Key facts
- Biotech M&A is on track for its best year since before the Covid-19 pandemic.
- Dealmaking is being driven by patent cliffs, buoyant public markets, and Big Pharma's need to bolster pipelines.
- The strong start to dealmaking is occurring in 2026.
Dealmaking in the biotechnology sector is experiencing a significant surge, positioning 2026 to be the strongest year for mergers and acquisitions since the pre-Covid era. Several key factors are fueling this trend. Companies are facing looming patent cliffs, which creates urgency to acquire new drugs or technologies. Additionally, public markets have become more buoyant, providing a more favorable environment for deal financing and valuations. Furthermore, large pharmaceutical companies are actively engaged in a race to enhance their drug pipelines through strategic acquisitions. This combination of pressures and opportunities is driving a robust start to M&A activity in the biotech space.